A Phase III, Multi-National, Multi-site, Open Label, 32 Week Long Term Follow-Up Study to Assess the Safety and Efficacy of the Engineered Human Anti-TNFa Antibody, CDP571, in Patients with Crohn's Disease

  • De Villiers, Willem (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date8/6/0110/31/03